Abstract
This study investigates the immune status of patients with inhalant allergy and acute respiratory viral diseases during ASIT given together with a bacterial derived liquid inducer of interferon (BLI), a preparation containing unique bacterial derived components (Kazakhstan government registration number RK-BP-3-000212) that induces synthesis of α- and β-IFNs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
